drugset / Trial / NCT04100473
Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus
Phase 2
Completed
24 enrolled
Dance Biopharm Inc.
Profil Institut für Stoffwechselforschung GmbH · collab
RandomizedCrossoverOpen-labelTreatment
Summary
This will be a randomized, open-label, active-controlled, 6-period crossover study. Target population will be subjects with Type 2 Diabetes Mellitus (T2DM)
Timeline
- Start
- 2018-04-23
- Primary completion
- 2018-08-11
- Completion
- 2019-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin | Protein / enzyme biologic | — | Inhaled |
| Comparator | Insulin Lispro | Protein / enzyme biologic | — | Subcutaneous |